Ascletis Pharma Inc.

Investors

2026

2025

2024

2023

2022

2021

2020

2019

2018

Next Day Disclosure Returns - Share Buyback
2023-10-03
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2023
2023-10-03
Next Day Disclosure Returns - Share Buyback
2023-09-29
Voluntary Announcement - Ascletis Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure
2023-09-29
Next Day Disclosure Returns - Share Buyback
2023-09-28
Next Day Disclosure Returns - Share Buyback
2023-09-27
Notification Letter with Request Form to Non-Registered Holders of Shares - Notice of Publication of Interim Report 2023
2023-09-27
Interim Report 2023
2023-09-27
Next Day Disclosure Returns - Share Buyback
2023-09-26
Voluntary Announcement - Ascletis Announces Completion of Enrollment of 120 Patients in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma
2023-09-26

7

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1